Claims

1. Use of an interleukin-13 (IL-13) binding protein in the manufacture of a medicament for the treatment of atopic dermatitis (AD) in a subject, wherein treatment with dupilumab did not result in ≥75% improvement of Eczema Area and Severity Index (EASI-75) compared to baseline, and wherein the IL-13 binding protein is to be administered to the subject subcutaneously, wherein the IL-13 binding protein is tralokinumab, and wherein: (a) a first dose of about 600 mg of the IL-13 binding protein is to be administered to the subject; and (b) one or more secondary dose(s) of about 300 mg of the IL-13 binding protein is to be administered to the subject, wherein each secondary dose is to be administered to the subject about 2 weeks or about 4 weeks after the immediately preceding dose, and wherein the treatment is to be carried out for at least 16 weeks.

2. The use according to claim 1, wherein a subject in which treatment with dupilumab did not result in ≥75% improvement of Eczema Area and Severity Index (EASI-75) compared to baseline, is to be selected.

3. The use according to claim 1 or claim 2, wherein the AD is inadequately controlled by cyclosporine A, such that treatment with cyclosporine A did not result in ≥75% improvement of Eczema Area and Severity Index (EASI-75) compared to baseline.

4. The use according to any one of the preceding claims, wherein the treatment is to be carried out for at least 24 weeks, at least 26 weeks, at least 6 months, at least 32 weeks, at least 36 weeks, at least a year, or at least 52 weeks or more.

5. The use according to any one of the preceding claims, wherein the tralokinumab is to be administered as a pharmaceutical composition comprising 50 mM sodium acetate buffer, 85 mM sodium chloride, 0.01% (w/v) polysorbate 80, wherein the pharmaceutical composition has a pH of 5.5.

6. The use according to any one of the preceding claims, wherein the IL-13 binding protein is to be administered as a monotherapy.

7. The use according to any one of the preceding claims, wherein the IL-13 binding protein is to be administered in combination with a second therapeutic agent selected from the group consisting of a topical corticosteroid, a topical calcineurin inhibitor, an anti-histamine, an emollient, or an anti-bacterial therapeutic.

8. The use according to claim 7, wherein the IL-13 binding protein is to be administered in combination with a topical corticosteroid.

9. The use according to any one of the preceding claims, wherein the treatment is capable of achieving ≥75% improvement of Eczema Area and Severity Index (EASI-75) compared to baseline.

10. The use according to claim 9, wherein the treatment is capable of achieving ≥75% improvement of Eczema Area and Severity Index (EASI-75) compared to baseline at week 16.

11. The use according to claim 9, wherein the treatment is capable of achieving ≥75% improvement of Eczema Area and Severity Index (EASI-75) compared to baseline at week 26.